本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
Preliminary data from Cohort 4 of the ENSURE study supports a novel enrichment strategy to utilize BRII-179 to identify patients who are immune responders and have the potential to achieve higher HBsAg loss at EOT 48-week EOT data from Cohort 1-3 of the ENSURE study clearly suggests the added benefits of elebsiran towards achieving a higher rate of HBsAg loss in combination with PEG-IFNα DURHAM, N.C. and BEIJING, China, March 30, 2025 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, announced new data from its ongoing Phase 2 ENSURE study as a late-breaking oral presentation at the 34th Annual Meeting of Asian Pacific Association for the Study of the Liver (APASL 2025) in Beijing, China. ENSURE (NCT05970289) is a multicenter, open-label Phase 2 study. Cohorts 1-3 were designed to evaluate the contribution of elebsiran, an investigational small interfering ribonucleic acid (siRNA), in combination with pegylated interferon alpha (PEG-IFNα) in participants with chronic HBV infection with baseline hepatitis B surface antigen (HBsAg) of 100-3,000 IU/mL. Participants who completed 9 doses of BRII-179, a recombinant protein-based therapeutic vaccine, in combination with elebsiran (BRII-835) in a previous APAC study BRII-179-835-001 (NCT04749368) were enrolled to Cohort 4 of this study and received elebsiran and PEG-IFNα combination treatment. The design of Cohort 4 as part of this study was based on insight from previous studies that a significant proportion of the chronic HBV patients fail to generate a sufficient immune response after receiving multiple doses of BRII-179, and therefore unlikely to have the immune support to achieve sustainable functional cure. Emerging data from Cohort 4 showed that participants who previously had BRII-179 induced anti-HBs response achieved a substantially higher rate of HBsAg seroclearance than those who did not. At Week 24, more than half of the BRII-179 responders (55.6% [10/18]) achieved HBsAg seroclearance, compared to only 10.0% (1/10) in non-responders. These latest data suggest that BRII-179 can serve as a predictive tool for enriching patients more likely to respond to curative therapies. Additional data from Cohorts 1-3 of the ENSURE study showed that higher end of treatment (EOT) HBsAg loss and seroconversion rates in participants receiving elebsiran in combination with PEG-IFNα than those receiving PEG-IFNα alone. "The positive Cohort 4 data from the ENSURE study opens new doors for HBV functional cure," said Dr. Grace Lai-Hung Wong, Professor of Gastroenterology and Hepatology at CUHK Medical Data Analytics Centre (MDAC) and Department of Medicine and Therapeutics in Hong Kong SAR, China. "Previous studies have suggested that BRII-179 may offer a unique opportunity to identify CHB patients who are able to elicit the necessary HBsAg antibody response. I believe these new findings provide clear evidence supporting such value proposition and further substantiate the role of BRII-179 in shaping future combination therapies." "We are encouraged that the Cohort 4 from the ENSURE study continue to support our enrichment strategy in developing a functional cure for chronic HBV in target populations," said David Margolis, MD, Chief Medical Officer of Brii Bio. "The results underscore the potential of BRII-179 in identifying patients who are more likely to respond to regimens aimed at functional cure, thereby enhancing functional cure rates in the target population while reducing exposure to costly therapies for those with a lower probability of cure. We are committed to advancing BRII-179 in combination with various modalities through our ongoing studies and collaborations with strategic partners, aiming to deliver higher functional cure rates to 254 million patients worldwide living with chronic HBV infection." Abstract Number: OP0335 Presentation Title: Responders to Prior BRII-179 Treatment Achieved Faster and Higher Rate of HBsAg Seroclearance Following Treatment of Elebsiran and PEG-IFNα in Participants with Chronic Hepatitis B Virus Infection: Preliminary Data from ENSURE Study Presenter: Grace Lai-Hung Wong, MBChB (CUHK), MD (CUHK), FRCP (Lond, Edin), FHKCP, FHKAM (Medicine), Professor of Gastroenterology and Hepatology at CUHK Medical Data Analytics Centre (MDAC) and Department of Medicine and Therapeutics in Hong Kong SAR, China Among the 28 of the 31 participants enrolled in Cohort 4 with baseline HBsAg ≥ 100 IU/mL being analyzed, 18 participants with peak anti-HBs ≥ 10 IU/L induced by prior BRII-179 treatment were defined as BRII-179 responders and 10 participants with peak anti-HBs < 10 IU/L were defined as non-responders. At Week 24 of treatment with elebsiran + PEG-IFNα, 39.3% (11/28) of the Cohort 4 participants achieved HBsAg seroclearance. The rate of HBsAg seroclearance at Week 24 in the BRII-179 responders was 55.6% (10/18), notably higher compared to the non-responders at 10% (1/10). Responders to prior BRII-179 treatment appeared to achieve a faster HBsAg seroclearance compared to BRII-179 naïve participants receiving elebsiran + PEG-IFNα as previously reported. Elebsiran and PEG-IFNα combination therapy was generally safe and well tolerated in participants with virally suppressed chronic HBV infection. Treatment with elebsiran + PEG-IFNα is ongoing for 48 weeks. Abstract Number: LB0009 Presentation Title: Higher end of treatment (EOT) HBsAg loss and seroconversion rates in participants with chronic HBV infection receiving elebsiran (BRII-835) and pegylated interferon alfa-2a (PEG-IFNα) compared to PEG-IFNα alone: Week 48 results from ongoing ENSURE study Presenter: Jidong Jia, M.D., Ph.D., Professor of Medicine at the Liver Research Centre, Beijing Friendship Hospital, Capital Medical University in Beijing, China The rates of HBsAg seroclearance at EOT in elebsiran 200 mg + PEG-IFNα and elebsiran 100 mg + PEG-IFNα cohorts were 26.3% (5/19) and 33.3% (6/18), respectively, notably higher compared to PEG-IFNα alone cohort (5.6%) in participants with baseline HBsAg levels 100-3,000 IU/mL. Greater HBsAg reductions at EOT were observed in elebsiran + PEG-IFNα combination cohorts (mean [SE]: -2.47 [0.28] or -3.01 [0.28] log10 IU/mL in elebsiran 200 mg or 100 mg, respectively) than in PEG-IFNα cohort (-1.02 [0.30] log10 IU/mL). Elebsiran in combination with PEG-IFNα at both 200 mg and 100 mg doses achieved similar HBsAg reductions and seroclearance rates. Elebsiran and PEG-IFNα combination therapy was generally safe and well tolerated in participants with virally suppressed chronic HBV infection. Post-treatment follow-up is ongoing and will continue for 24 weeks after discontinuation of treatment. As part of Brii Bio's unique approach to developing a functional cure for HBV, the Company and its partners are actively progressing multiple combination studies with our differentiated portfolio, including BRII-179, a recombinant protein-based HBV immunotherapeutic being evaluated in multiple combination studies with elebsiran led by Brii Bio; elebsiran being evaluated in combination with PEG-IFNα in studies led by Brii Bio and tobevibart, an investigational broadly neutralizing monoclonal antibody targeting HBV, being evaluated in multiple Phase 2 and 3 tobevibart and elebsiran combination studies led by Vir Biotechnology. Key data readouts will be shared in the coming months at the scientific conferences throughout 2025. About Hepatitis B Hepatitis B virus (HBV) infection is one of the world's most significant infectious disease threats with more than 254 million people infected globally.[1] Chronic HBV infection is the leading cause of liver disease and an estimated 820,000 people die of complications from chronic HBV infection each year.[1] HBV is of exceptional concern in China, where 87 million people are chronically infected.[2] About BRII-179 BRII-179 is a novel recombinant protein-based HBV immunotherapeutic candidate that expresses the Pre-S1, Pre-S2, and S HBV surface antigens, and is designed to induce enhanced and broad B-cell and T-cell immunity. In November 2023, the Center for Drug Evaluation (the "CDE") of the National Medical Products Administration (the "NMPA") granted BRII-179 Breakthrough Therapy Designation. About Elebsiran (BRII-835, VIR-2218) Elebsiran is an investigational subcutaneously administered HBV-targeting siRNA designed to degrade hepatitis B virus RNA transcripts and limit the production of hepatitis B surface antigen. It has the potential to have direct antiviral activity against HBV and HDV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index. Brii Bio licensed exclusive rights to develop and commercialize elebsiran for the Greater China territory from Vir Biotechnology, Inc. in 2020. About Brii Bio Brii Biosciences Limited ("Brii Bio", stock code: 2137.HK) is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases, the Company is advancing a broad pipeline of unique therapeutic candidates with lead programs against hepatitis B virus (HBV) infection. The Company is led by a visionary and experienced leadership team and has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. For more information, visit www.briibio.com. [1] World Health Organization. (April 2024). Global hepatitis report 2024: action for access in low- and middle-income countries. World Health Organization. Retrieved from https://www.who.int/publications/i/item/9789240091672 [2] World Health Organization. Hepatitis. World Health Organization. Retrieved from https://www.who.int/china/health-topics/hepatitis#:~:text=There%20are%2087%20million%20people,living%20with%20chronic%20hepatitis%20C.
HO CHI MINH CITY, Vietnam, March 30, 2025 /PRNewswire/ -- Anker Innovations, a global leader in mobile charging and consumer electronics, is redefining the boundaries of innovation with its latest campaign, Charge Up, SEA!—an electrifying fusion of augmented reality (AR) and computer-generated imagery (CGI) set to energize Southeast Asia. These experiences allow users to interact with technology and explore the future of charging, reinforcing Anker's leadership in global innovation. "At Anker, our mission is to ignite possibilities through ultimate innovation," said Leon Wu, General Manager of Southeast Asia at Anker Innovations. "We've not only created products that lead the industry in performance but also ones that fundamentally change the way people engage with power. This campaign reflects our vision of an interconnected world where innovation enhances the everyday lives of Southeast Asia consumers." Revolutionizing Charging with Anker At the core of Charge Up, SEA! is Anker's most advanced charging lineup to date, the Anker Prime Series. This revolutionary series redefines multi-device fast charging, offering a powerful, intelligent, and interactive solution that transforms what was once a passive task into an engaging experience. Designed with extensive user insights, the Anker Prime Series is engineered to be the ultimate power source for today's fast-paced, tech-driven world, empowering users with speed, efficiency, and innovation. This innovation powers Charge Up, SEA!, an AR-driven journey that brings Anker's cutting-edge technology to life by "charging" iconic landmarks across Southeast Asia. The visual narrative of the campaign showcases Anker Prime chargers energizing these landmarks, reflecting the brand's commitment to efficient and intelligent charging solutions. Through advanced AR technology, Anker's innovations seamlessly integrate into the cityscapes, reinforcing its position as the leader in next-generation charging while reshaping how users experience power in an increasingly connected world. Lights Up the City's landmark with Ultimate Innovation Starting February 27, "Charge Up, SEA!" will light up five countries—Singapore, Malaysia, the Philippines, Indonesia, and Vietnam—through immersive digital storytelling and interactive experiences. In Singapore and Malaysia, users will have the exclusive opportunity to experience Anker's AR world in person at key landmarks, while all five countries will engage with high-quality CGI videos that bring Anker Prime to life. These experiences allow users to interact with technology and explore the future of charging, reinforcing Anker's leadership in global innovation. For the Charge Up, SEA! campaign, Anker will launch a futuristic CGI video in Vietnam. The creative concept features the supertall Landmark 81 skyscraper in Ho Chi Minh City as a physical backdrop, seamlessly integrating Anker's innovative technology with local culture, resulting in a visually striking fusion of cutting-edge technology and heritage. In this CGI video, Anker innovatively creates a stunning virtual space, with the Anker 30W Zolo Charger acting as the key to unlock this realm. The charger powers up the Landmark 81, and thanks to its outstanding temperature control, the space is immediately enveloped in polar ice and snow. This transformation sparks an innovative interaction between the landmark and the virtual world. To further energize the virtual space, the Anker 25,000mAh 165W Power Bank, the Anker 140W Charger, and the Anker Prime 250W GaN Desktop Charger deliver a continuous flow of high-speed power, keeping the experience alive. Engaging with the dynamic world, consumers will witness how Anker's advanced charging technology seamlessly integrates into this digital universe, providing a truly futuristic experience and a glimpse into the future of connected, intelligent charging. Powering the Future with Limitless Possibilities As a global pioneer in charging technologies, Anker consistently integrates user feedback and cutting-edge research to drive its innovation. With its innovations, Anker offers a glimpse into the future of sustainable, efficient power that is both portable and powerful—ideal for the modern, always-connected consumer. As Anker expands its presence in Southeast Asia, the Charge Up, SEA! campaign reaffirms its commitment to pioneering innovation and user-centered design. By merging cutting-edge digital experiences with state-of-the-art charging technology, Anker is not just powering devices—it's reshaping how consumers connect with the future. Anker invites consumers across Southeast Asia to experience the next generation of charging—where every city, every device, and every moment is powered by limitless possibilities. About Anker Anker is the world's #1 mobile charging brand and a developer of high-speed charging technologies for the home, car, and on the go. This includes wall plugs, wireless chargers, car chargers, power banks, cables, and more. Find out more about Anker at anker.com.
HONG KONG, March 30, 2025 /PRNewswire/ -- On March 24, the launch ceremony of ADC Submarine Cable's commissioning was successfully held at the Everbright Centre in Hong Kong. The event brought together over a hundred distinguished guests, including prominent figures from the political and business sectors, industry experts, and representatives from leading media organizations. The ADC Submarine Cable project is jointly constructed by China Telecom, China Unicom, Singapore Telecom, Japan's SoftBank, TATA Communications, Vietnam's VIETTEL, Thailand's NT, and the Philippines' PLDT. As the only international submarine cable initiative launched in the Asia-Pacific region over the past nine years, it boasts the highest system transmission capacity and the largest number of fiber pairs in the region. Spanning 9,988 kilometers, the ADC Submarine Cable links mainland China, Hong Kong, Japan, Singapore, and multiple other countries and regions across the Asia-Pacific. Designed with an open cable architecture and cutting-edge high-capacity optical transmission technology, it features a per-fiber pair design capacity exceeding 20 Tb/s, with a total system capacity surpassing 160 Tb/s. By offering diverse routing options, the ADC Submarine Cable significantly strengthens network resilience and stability across the Asia-Pacific, reinforcing the region's digital infrastructure. At the event, Prof. Sun Dong, Secretary for Innovation, Technology and Industry, the Government of HKSAR, emphasized that as a key gateway for the country's opening-up, Hong Kong will fully harness its unique advantages under the "one country, two systems" framework. Leveraging its strategic roles as a "super connector" and "super value-adder," Hong Kong aims to facilitate the global expansion of mainland enterprises while attracting international businesses. The Hong Kong SAR Government remains committed to enhancing the innovation and technology ecosystem through institutional innovation, policy coordination, and international collaboration. He encouraged industry leaders, including China Telecom, to embrace national and SAR government initiatives, capitalize on the opportunities presented by the digital economy, and intensify R&D efforts to drive breakthroughs in artificial intelligence, big data, and other frontier technologies. At the same time, he expressed confidence that more enterprises would actively contribute to Hong Kong's innovation and technology landscape, fostering an open and inclusive ecosystem and reinforcing the city's position as a globally influential hub for technological advancement. Ms. Liu Ying, Executive Vice President of China Telecommunications Corporation Ltd. (hereinafter referred to as "China Telecom"), indicated that the official launch of the ADC Submarine Cable marks a significant milestone in international cooperation. This achievement not only reaffirms China Telecom's long-standing commitment to its global expansion strategy, cloud-network integration, and digital transformation but also ushers in a new era of collaboration with global partners to drive technological progress and shared prosperity. She also highlighted that China Telecom's international business will continue to leverage Hong Kong as a strategic hub, dedicated to fostering a more open and collaborative ecosystem, advancing digital technology innovation, and accelerating the growth of the digital economy. The company remains committed to delivering more efficient, secure, and intelligent communication services to global users while working with industry partners to build a dynamic, inclusive, and mutually beneficial digital landscape. As one of the organizers of the ADC Submarine Cable project, Mr. Yin Jin, CEO of China Telecom Global introduced that the ADC Submarine Cable will add over 50 Tb/s of bandwidth capacity to the Asia-Pacific region, supporting the exponential growth in data demand driven by artificial intelligence, the Internet of Things, and cloud computing. By offering a high-speed and resilient submarine communication network, the project not only enhances international telecommunications cooperation but also plays a vital role in fostering the high-quality development of the digital economy. In alignment with Hong Kong's vision of becoming an International Innovation and Technology Hub, China Telecom Global is accelerating the development of major infrastructure projects, including the Tseung Kwan O Data Center, the Chung Hom Kok Cable Landing Station, and the New Eurasia and New Asia-Pacific submarine cables. The company is also strengthening its R&D capabilities through the establishment of AI and cybersecurity innovation centers, reinforcing its long-term commitment to driving technological progress and contributing to Hong Kong's continued prosperity. As the backbone of the global internet, submarine cables serve as a vital lifeline for international data transmission. In the future, China Telecom will collaborate with major global operators to continuously promote more submarine cable construction projects, further reinforcing the infrastructure that underpins 5G, AI, and digital technologies. By enhancing global connectivity, the company aims to accelerate the digital transformation landscape and contribute to the high-quality advancement of the digital economy.
BHUBANESWAR, India, March 30, 2025 /PRNewswire/ -- KIIT Deemed to be University (https://kiit.ac.in/), Bhubaneswar, India, continues to expand its global footprint through strategic partnerships with reputed international institutions. It has recently signed Memoranda of Understanding (MoUs) with three prestigious universities - the University of Tulsa (USA), Toi Ohomai Institute of Technology (New Zealand), and the University of Washington-Bothell (USA). These collaborations offer students and faculty enhanced academic and research opportunities. The Founder of KIIT and KISS Dr Achyuta Samanta along with the senior functionaries of both KIIT and University of Washington with the students and teachers of both varsities during a signing of academic exchange initiatives and felicitation function. As part of its global education initiative, KIIT has partnered with the University of Tulsa, Oklahoma, USA, to launch a dual degree program in B.Tech. This 2+2 model allows students to complete two years at KIIT and the remaining two years at the University of Tulsa, earning a degree from both institutions. Beyond the dual degree program, 40 KIIT students from various disciplines, including engineering and liberal studies, will participate in short-term courses at the University of Tulsa, gaining hands-on experience and international exposure. This partnership also facilitates faculty exchanges, joint research projects, and sabbatical opportunities between the two institutions. Further strengthening its international presence, KIIT has signed an MoU with Toi Ohomai Institute of Technology, New Zealand. Signed in the presence of Mr. Christopher Luxon, Hon'ble Prime Minister of New Zealand, the partnership aims to enhance teaching and research capabilities, focusing on articulation pathways in commerce and management at both undergraduate and postgraduate levels. Toi Ohomai is a leading vocational and applied tertiary education provider known for its industry-aligned programs and hands-on learning approach. KIIT has also forged an impactful academic collaboration with the University of Washington-Bothell (UWB), USA, through an immersive learning initiative. A delegation of 18 members from UWB, during their visit to KIIT, worked with KIIT's management students to analyze real-world business challenges faced by local enterprises and develop sustainable solutions. This initiative brought together students from both universities, providing them with valuable international exposure and practical learning experiences. The collaboration represents an innovative model for global academic engagement, encouraging universities to move beyond traditional exchange programs and embrace collaborative teaching models. With over 350 MoUs signed with leading universities and corporations worldwide, KIIT has established itself as a hub for academic excellence and cultural exchange. Dr. Achyuta Samanta, Founder, KIIT, KISS & KIMS, emphasized the importance of such collaborations in equipping students with a global perspective, AI integration, and skill development opportunities that align with the evolving global workforce. https://www.youtube.com/watch?v=37xY6DvQgdA
JAKARTA, Indonesia, March 29, 2025 /PRNewswire/ -- PT Bank Rakyat Indonesia (Persero) Tbk (IDX: BBRI) held its Annual General Meeting of Shareholders (AGMS). At this year's AGMS, BRI approved the distribution of dividends amounting to IDR 51.73 trillion, an increase compared to the 2024 dividend of IDR 48.10 trillion. In addition, BRI will also carry out a share buyback of up to IDR 3 trillion. The executives during the 2025 Annual General Meeting of Shareholders (AGMS) BRI's 2025 AGMS approved 10 agenda items, with three key topics highlighted by Corporate Secretary Agustya Hendy Bernadi: dividend distribution, share buyback, and management changes. Use of the Company's Net Profit (Cash Dividend Distribution) For the 2024 fiscal year, BRI posted a consolidated net profit of IDR 60.15 trillion, allocating up to IDR 51.73 trillion for cash dividends. An interim dividend of IDR 20.33 trillion (IDR 135 per share) was distributed on January 15, 2025, leaving a remaining payout of up to IDR 31.40 trillion. Of the total, IDR 27.68 trillion will go to the state, with the rest distributed proportionally to shareholders listed on the recording date. Share Buyback Plan In addition to the dividend distribution, BRI's 2025 AGMS also approved the company's plan to repurchase or buy back shares in an amount of up to IDR 3 trillion. The buyback will be carried out through the Stock Exchange or outside the Stock Exchange. Changes to the Company's Management The 2025 AGMS resolved changes to the company's management, including the honorable discharge of the following 19 individuals, among them Sunarso as President Director and Catur Budi Harto as Deputy President Director. Additionally, BRI appointed 16 individuals, including Hery Gunardi as President Director and Hakim Putratama as Director of Operations. The AGMS also reassigned Agus Noorsanto from Director of Wholesale and Institutional Business to Deputy President Director, and Ahmad Solichin Lutfiyanto from Director of Compliance to Director of Human Capital & Compliance. In total, BRI's 2025 AGMS discussed and resolved 10 agenda items. The complete resolutions are available on the BRI website at www.bri.co.id "The decisions made in this AGMS reflect BRI's commitment to continuously improve performance and deliver added value to shareholders and other stakeholders," concluded Hendy. For more information about BANK BRI, visit www.bri.co.id
SAN FRANCISCO, March 29, 2025 /PRNewswire/ -- Eoptolink Technology Inc., Ltd. (SZSE: 300502), a leading innovator and provider of advanced optical transceiver solutions, will be demonstrating its second generation of fully retimed 1.6T OSFP transceivers operating during OFC 2025. The second generation of fully retimed 1.6T OSFP and OSFP-RHS transceivers use a 3nm DSP and support enhanced monitoring capabilities for 1.6T and per 200G channel basis. Offering modules based on 3nm DSP will reduce the overall module power consumption by around 20%. Enhanced VDM functionality will enable the reporting of pre and post FEC bit error rates as well as symbol error distributions. The second generation 1.6T OSFP offering includes: EOLO-13T-5H-xDxx, 2DR4 OSFP with 2 MPO-12 connectors EOLO-16T-02-xxx, 2FR4 OSFP with 2 duplex LC connectors Both Silicon Photonics and EML variants are available for the above types. "3nm DSPs will accelerate the adoption of 1.6T transceivers", explains Sean Davies, VP Sales, Eoptolink Technology Inc., Ltd. "More and more 200G SerDes based Ethernet platforms are becoming available thus expanding the addressable market. The reduced power consumption and enabling of advanced monitoring features are welcomed by Ethernet equipment vendors and hyperscalers. We are very pleased to be able to offer OSFP and OSFP-RHS variants." We will be showing live demonstrations of a 1.6T, 800G, LPO, LRO and MCF optical transceiver solutions, at the Eoptolink booth #2943 at OFC 2025, San Francisco, CA. You are welcome to come and visit us. About Eoptolink Eoptolink Technology Inc., Ltd. (SZSE: 300502) is a leading innovator and provider of advanced optical transceiver solutions for data center, enterprise and telecom networks. Eoptolink is dedicated to research, develop, manufacture and markets a diverse portfolio of high-performance optical transceivers for AI/ML Cluster, Cloud Data Center, 4G/5G wireless, Transport & Datacom and FTTX applications all over the world. Contact Us USA: 3191 Laurelview Court, Fremont, CA 94538Thailand: 390/21 Moo 2, Khao Khan Song, Sriracha, Chonburi 20110China(HQ): No.510 Wulian Avenue, Chengdu 610200E-mail: sales@eoptolink.com
Computer/Electronics
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
